PARIS and NEW YORK, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that it will release the results of the Phase IIa clinical trial for high blood pressure (QGC001 program) on September 29, 2016, after the close of Euronext Paris.
As a reminder, this clinical trial evaluated around 30 patients with high blood pressure at four clinical investigation centres in France, under the supervision of Prof. Michel Azizi, Clinical Investigation Centre at Georges Pompidou European Hospital, Paris. It was a randomised, double-blinded study, with cross-over, to compare the effects of the product QGC001 (500 mg morning and night) with those of a placebo. It also aimed to analyse the pharmacodynamic effects of QGC001 on several hormonal biomarkers.
ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).
The Company has offices in Paris, France and New York, NY, USA. For more information, please visit www.quantum-genomics.com.
Twitter: @ALQGC_EN
LinkedIn: Quantum Genomics